Clinical Trial Update: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for enzalutamide in nonmetastatic castration-resistant prostate cancer; the study is completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmetastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-07-12